Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

Molecular Landscape Involved in the Onset of Breast Cancer in Patients With Germline BRCA-1/2 Mutations, During or After Therapy With Platinum-based Agents and/or PARP-inhibitors for Ovarian Cancer

This study will investigate, in patients with germline BRCA-1/2 mutations and breast cancer, arising during and / or after treatment with platinum-based chemotherapy and / or with PARP-inhibitors for ovarian cancer, the presence of molecular alterations potentially involved in the mechanisms of resistance to antineoplastic treatment on breast and ovarian tumor tissue.

Inclusion Criteria:

• Written informed consent.
• Age older than 18 years.
• Germline BRCA1/2 mutation.
• Histologically confirmed ovarian cancer treated with platinum-based chemotherapy and/or PARP inhibitors.
• Histologically confirmed breast cancer occurred during or after therapy with platinum-based agents and/or PARP-inhibitors for ovarian cancer.
• Availability of FFPE breast and ovarian tumor samples.

Exclusion Criteria:

• Other malignancies in the last 2 years.
• Prior chemotherapy or radiation therapy for other malignancies.